Small molecule · developed by Minerva Neurosciences
Roluperidone is an investigational agent studied in negative symptoms of schizophrenia, and in healthy subjects.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07565428 | Phase 3 | Negative Symptoms of Schizophrenia | Recruiting | NERV |
| NCT03397134 | Phase 3 | Negative Symptoms of Schizophrenia | Completed | NERV |
| NCT03038646 | Phase 1 | Healthy Subjects | Completed | NERV |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy SubjectsNegative Symptoms of Schizophrenia
Updated Oct 25, 2026. Something wrong or missing? Report it on the NERV page.
See NERV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NERV catalysts and pipeline →